GoodRx Holdings, Inc. GDRX PHARMA
Company Overview
GoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices. It also offers other healthcare products and services, including subscription programs and pharma manufacturer solutions, as well as telehealth services through the GoodRx Care platform. In addition, the company provides healthcare products and solutions for dogs, cats, and other pets. It serves pharmacy benefit managers who manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was founded in 2011 and is headquartered in Santa Monica, California.
Why Investors Should Care
Revenue has grown at a 18.0% CAGR over the past five years.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $796.85M (+0.6% YoY); net profit $30.44M.
- Trailing 12 Months Year-on-year growth — revenue -1.3%, earnings -44.5%.
- 5-Year Trend Long-term compounding — revenue CAGR 18.0%, profit CAGR -5.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 18.04% |
| 1 Year: | -1.30% |
Compounded Profit Growth
| 5 Years: | -5.06% |
| 1 Year: | -44.50% |
Stock Price Performance
| 1 Year: | -1.12% |
| 6 Months: | +49.79% |
| 3 Months: | +33.84% |
| 1 Month: | -4.35% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)53.66 · Neutral
P/E of 58.67 is above the sector median of 24.83 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 18.0% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading at a high P/E of 58.7.
- Earnings shrank at -5.1% CAGR over 5 years.
- Trading 31.2% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | GDRX GoodRx Holdings, Inc. PHARMA | 3.52 | 58.67 | $377.28M | 0.00% | 7.56% | 2.52% | 18.04% | -5.06% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 101.75M | 133.41M | 123.30M | 140.45M | 160.43M | 176.63M | 195.10M | 203.33M | 191.80M | 187.32M | 183.99M | 189.68M | 179.96M | 197.88M | 200.61M | 195.25M | 202.97M | 203.07M | 196.03M | 194.01M | 200.41M |
| Operating Income | - | - | 37.84M | 43.67M | 41.74M | -61.69M | -5.00M | -351.00K | 7.00M | 19.76M | -4.05M | -15.71M | 11.30M | 18.31M | -38.33M | 7.38M | 19.88M | 20.41M | 23.38M | 26.81M | 14.62M | 14.01M | 23.63M |
| Net Income | 11.55M | 19.65M | 19.62M | 27.35M | 27.34M | -50.03M | 1.67M | 31.06M | -18.07M | 12.29M | -1.42M | -41.73M | -3.29M | 58.79M | -38.49M | -1.01M | 6.69M | 3.96M | 11.05M | 12.84M | 1.12M | 1.17M | 8.54M |
| Diluted EPS | - | - | 0.05 | 0.08 | 0.08 | -0.21 | 0.00 | 0.07 | -0.04 | 0.03 | 0.00 | -0.10 | -0.01 | 0.14 | -0.09 | 0.00 | 0.02 | 0.01 | 0.03 | 0.04 | 0.00 | 0.00 | 0.02 |
| R&D Expense | - | - | 7.84M | 10.32M | 11.96M | 15.85M | 26.16M | 29.57M | 35.07M | 35.04M | 35.40M | 35.92M | 32.91M | 31.29M | 39.61M | 31.02M | 30.85M | 30.14M | 31.14M | 29.93M | 31.01M | 30.18M | 26.71M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 249.52M | 388.22M | 550.70M | 745.42M | 766.55M | 750.26M | 792.32M | 796.85M |
| Operating Income | 77.25M | 139.68M | -275.72M | 13.41M | 1.74M | -27.01M | 65.85M | 87.49M |
| Net Income | 43.79M | 66.05M | -293.62M | -25.25M | -32.83M | -8.87M | 16.39M | 30.44M |
| Diluted EPS | 0.12 | 0.18 | -1.07 | -0.06 | -0.08 | -0.02 | 0.04 | 0.09 |
| R&D Expense | 43.89M | 29.30M | 61.82M | 125.86M | 143.14M | 135.84M | 123.75M | 121.03M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 386.80M | 1.47B | - | 1.60B | 1.59B | 1.39B | 1.40B |
| Current Assets | - | - | - | - | - | 919.69M | 872.79M | 659.25M | 643.10M |
| Cash & Equivalents | - | 34.60M | 26.05M | 968.69M | - | 757.16M | 672.30M | 448.35M | 261.82M |
| Inventory | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | 117.14M | 143.61M | 145.93M | 235.75M |
| Total Liabilities | - | - | 737.37M | 758.75M | - | 789.80M | 826.84M | 663.41M | 787.80M |
| Current Liabilities | - | - | 33.37M | 59.55M | - | 76.32M | 122.56M | 123.90M | 246.00M |
| Long Term Debt | - | - | 663.89M | 659.89M | - | 651.80M | 647.70M | 486.71M | 483.26M |
| Total Debt | - | - | - | - | - | 717.02M | 711.07M | 543.39M | 542.81M |
| Total Equity | -31.75M | -1.16B | -1.09B | 711.36M | - | 814.83M | 761.96M | 724.66M | 616.26M |
| Shares Outstanding | - | - | - | - | - | 397.02M | 394.09M | 382.81M | 341.05M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 45.25M | 83.29M | 131.34M | 178.78M | 146.78M | 138.29M | 183.89M | 167.90M |
| Investing Cash Flow | -3.46M | -37.05M | -91.62M | -178.73M | -210.50M | -55.77M | -70.35M | -119.96M |
| Financing Cash Flow | -24.73M | -54.78M | 905.82M | -30.53M | -120.23M | -167.40M | -337.50M | -234.47M |
| Capital Expenditure | -804.00K | -1.43M | -20.55M | -4.57M | -3.97M | -1.04M | -1.24M | -3.52M |
| Free Cash Flow | 44.45M | 81.86M | 110.79M | 174.21M | 142.81M | 137.25M | 182.65M | 164.38M |
| Share Buybacks | - | - | 0 | 0 | 101.72M | 103.97M | 158.84M | 216.37M |
| Dividends Paid | 1.35B | - | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - |
| Operating Margin % | 31.0% | 36.0% | -50.1% | 1.8% | 0.2% | -3.6% | 8.3% | 11.0% |
| Net Margin % | 17.6% | 17.0% | -53.3% | -3.4% | -4.3% | -1.2% | 2.1% | 3.8% |
| ROE % | -3.8% | -6.1% | -41.3% | - | -4.0% | -1.2% | 2.3% | 4.9% |
| ROCE % | - | 39.5% | -19.5% | - | 0.1% | -1.8% | 5.2% | 7.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Francisco Partners Management, LP | 57.38% | 60.08M | $203.06M |
| 2 | LSV Asset Management | 4.92% | 5.16M | $17.43M |
| 3 | Ameriprise Financial, Inc. | 4.53% | 4.75M | $16.04M |
| 4 | Vanguard Capital Management LLC | 3.90% | 4.09M | $13.81M |
| 5 | Silver Lake Group, LLC | 3.37% | 3.53M | $11.94M |
| 6 | Renaissance Technologies, LLC | 3.10% | 3.25M | $10.97M |
| 7 | Vanguard Portfolio Management LLC | 3.06% | 3.21M | $10.84M |
| 8 | Petrus Trust Company, LTA | 2.96% | 3.10M | $10.47M |
| 9 | Dimensional Fund Advisors LP | 2.45% | 2.56M | $8.65M |
| 10 | AQR Capital Management, LLC | 2.22% | 2.33M | $7.86M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for GDRX
GoodRx (GDRX) Stock Looks Overvalued On Its Earnings Outlook - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxOWXJVbEdBWFNJdVlSX2taTlYwMHN6S3lsT29rTFZQOWNhNkhSQWZUUnNqbGtKdW16NkNUckNuWmlEU0JKdE5peG54WUQ3MGdoTzhDZWdPcm94blRxUl81MzRMM08yNWtmTDVBZDRGSGhqcVZFMkZXWWxBU21ISGxfYUVqLXVYak1jdVdUd3…
One plan covers kids, adults and pets. GoodRx's new membership costs $24.99 a month. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxNMHpVM3c0STNlSnlZYzE4dm53V1hGeWRIWUhtaDh4QW1FWExzRkk1cUlabzJTTF9Ea2o4THpsNHNCbkRDdFU2eERnWExkZThSbmJLZ093M3NwOHhRU0lmMTRWb2x4R1dwNWg5YUFkQ21ST01aTEFMN042bmdfWUw5LUdWS3dNZDdpWW5RQm…
GoodRx (GDRX) Stock Trades At A Premium On Earnings Despite Weak Returns - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxNQWNlalhqeXBDOUVfb0s2ZzJjcjhSc19SMDE4Vjcyanc2NjBjUmNlNmRDOEFTazROUm5LbzZ2VkNFS1lmTGZJTkdYN3UteWNTNjVoSDJ1WDFKWm9CZlliXzJIcko2OVh2bGlNZ1J3ZXZWVnd6dGVEbHJxVGwxa3ZWQW93YU9HM2FwblJ3bH…
GoodRx (GDRX) Stock Trades Up, Here Is Why - StockStory
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxNY2w1Q2txcDAxcFVYcFRPakxtaHI4MGFjYlJQRXRMM3F3S3hnbUt0b216cDZkNmVrTTdaZGJKS0QwWHd2VTBqQlRLV05vNjh1c1FyclVRRkRITEJxdWVNTGhZNVpIY1QxSFBVdnl0bXZsUFpXT1J1Y3lTaHBEdHpmYWRMS2dQWmV3QVFET1…
GoodRx Stock (GDRX) Opinions on TrumpRx Partnership - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxPMGUyYmdTaThSWGcxX01xbmp1TGdLQk4zcmxxTFBoak9zMGZ2bTlZZ1AxcEMyOUtUVjc4Y2psOFgxM21wSWN4NGRELU5TeWd0eU5CNjM2S2NqSXZnakU0RFZjN1BnV0hUVUozeklNSmpvQkFNVHFrTUR1V0lyYVVUd0JiNjdNTDNHc3p2ZG…
GDRX Looks 34.8% Undervalued on GF Value™ - gurufocus.com
<a href="https://news.google.com/rss/articles/CBMigwFBVV95cUxPdEY3U2YwR2k2SjNvdTZRZTN3UVFTeHIxcEdpSkVpSHpVRjhVYjJ5Z2dpSnpDZ3dDUHh6WHZrRkJka3JxZzBWYVBuay1OUjVRYWJQWlBWNUZNVEJoTjZpbWVYSDlFUU9ja19JN2lSdW1JV1VrWjhlN0NYVkxRLTR3aHVSaw?oc=5" targe…
GDRX — Frequently Asked Questions
What is the current share price of GoodRx Holdings, Inc. (GDRX)?
As of 2026-09-19 21:16 PDT, GoodRx Holdings, Inc. (GDRX) trades at $3.52 on NasdaqGS. Its 52-week range is $1.87 to $5.12.
What is the market capitalisation of GDRX?
GoodRx Holdings, Inc. (GDRX) has a market capitalisation of $377.28M on NasdaqGS.
What is the P/E ratio of GDRX?
GDRX trades at a trailing price-to-earnings (P/E) ratio of 58.67. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.78.
What is the return on equity (ROE) of GDRX?
GDRX has a return on equity (ROE) of 2.52%. Its return on capital employed (ROCE) is 7.56%.
Is GDRX a good stock to buy?
This page provides a data-driven analysis of GoodRx Holdings, Inc. (GDRX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.